Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 15/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7921019 | 1.00 | HDAC1 (0.43) | HDAC1HDAC6HDAC3HDAC2HDAC8 | |
| SCHEMBL3692466 | 0.90 | MEN1 (0.36) | MEN1HPGDKMT2ANPSR1 | |
| SCHEMBL7917993 | 0.90 | HDAC1 (0.52) | HDAC1HDAC6HDAC3HDAC2HDAC8 | |
| SCHEMBL18082010 | 0.89 | HDAC1 (0.44) | HDAC1HDAC6HDAC3HDAC2HDAC8 | |
| SCHEMBL18082003 | 0.89 | HDAC1 (0.44) | HDAC1HDAC6HDAC3HDAC2HDAC8 | |
| SCHEMBL5676195 | 0.87 | KMT2A (0.37) | MEN1HPGDKMT2ANPSR1 | |
| SCHEMBL5676198 | 0.87 | KMT2A (0.37) | MEN1HPGDKMT2ANPSR1 | |
| SCHEMBL366334 | 0.87 | KMT2A (0.38) | MEN1HPGDKMT2ANPSR1 | |
| SCHEMBL29468020 | 0.87 | KMT2A (0.38) | MEN1HPGDKMT2ANPSR1 | |
| SCHEMBL13338135 | 0.87 | KMT2A (0.38) | MEN1HPGDKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46144-E1 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9096627-B2 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140066419-A1 | HYDROXAMIC ACID DERIVATIVES | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20110269706-A1 | Hydroxamic Acid Derivatives | NORTHLAKE BIOSCIENCES LLC (US) | 2011-11-03 | — | — | US | disclosed |
| WO-2010085377-A2 | HYDROXAMIC ACID DERIVATIVES | CRYSTAL BIOPHARMACEUTICAL LLC (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066419-A1 | HYDROXAMIC ACID DERIVATIVES | HDAC5, HDAC7, HDAC4 | HDAC1 4/4885HDAC6 7/4885HDAC3 10/4885 |
| US-20110269706-A1 | Hydroxamic Acid Derivatives | CD74, HLA-DRB1, HDAC5 | HDAC1 7/4885HDAC6 12/4885HDAC3 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.